176 related articles for article (PubMed ID: 30241415)
1. Whole Exome Sequencing Identifies a Novel Hedgehog-Interacting Protein G516R Mutation in Locally Advanced Papillary Thyroid Cancer.
Lee WK; Lee SG; Yim SH; Kim D; Kim H; Jeong S; Jung SG; Jo YS; Lee J
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30241415
[TBL] [Abstract][Full Text] [Related]
2. Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations.
Pan W; Zhou L; Ge M; Zhang B; Yang X; Xiong X; Fu G; Zhang J; Nie X; Li H; Tang X; Wei J; Shao M; Zheng J; Yuan Q; Tan W; Wu C; Yang M; Lin D
Hum Mol Genet; 2016 May; 25(9):1875-84. PubMed ID: 26941397
[TBL] [Abstract][Full Text] [Related]
3. The Profile of Genetic Mutations in Papillary Thyroid Cancer Detected by Whole Exome Sequencing.
Fang Y; Ma X; Zeng J; Jin Y; Hu Y; Wang J; Liu R; Cao C
Cell Physiol Biochem; 2018; 50(1):169-178. PubMed ID: 30278442
[TBL] [Abstract][Full Text] [Related]
4. Whole-exome sequencing and bioinformatic analyses revealed differences in gene mutation profiles in papillary thyroid cancer patients with and without benign thyroid goitre background.
Eng ZH; Abdullah MI; Ng KL; Abdul Aziz A; Arba'ie NH; Mat Rashid N; Mat Junit S
Front Endocrinol (Lausanne); 2022; 13():1039494. PubMed ID: 36686473
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
6. Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis.
Jeon MJ; Chun SM; Lee JY; Choi KW; Kim D; Kim TY; Jang SJ; Kim WB; Shong YK; Song DE; Kim WG
Endocrine; 2019 Apr; 64(1):130-138. PubMed ID: 30645724
[TBL] [Abstract][Full Text] [Related]
7. Determination of the mutational landscape in Taiwanese patients with papillary thyroid cancer by whole-exome sequencing.
Chang CC; Chang YS; Huang HY; Yeh KT; Liu TC; Chang JG
Hum Pathol; 2018 Aug; 78():151-158. PubMed ID: 29753010
[TBL] [Abstract][Full Text] [Related]
8. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
9. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
10. Somatic Mutation Profiling of Papillary Thyroid Carcinomas by Whole-exome Sequencing and Its Relationship with Clinical Characteristics.
Qi T; Rong X; Feng Q; Sun H; Cao H; Yang Y; Feng H; Zhu L; Wang L; Du Q
Int J Med Sci; 2021; 18(12):2532-2544. PubMed ID: 34104084
[TBL] [Abstract][Full Text] [Related]
11. Expression and Function of Long Noncoding RNA NONHSAT129183 in Papillary Thyroid Cancer.
Ding J; Wang F; Xiang T; Qiao M
Oncol Res; 2018 Aug; 26(7):1047-1053. PubMed ID: 29321094
[TBL] [Abstract][Full Text] [Related]
12. Concomitant high expression of ERĪ±36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior.
Dai YJ; Qiu YB; Jiang R; Xu M; Liao LY; Chen GG; Liu ZM
Cell Oncol (Dordr); 2018 Jun; 41(3):269-282. PubMed ID: 29368272
[TBL] [Abstract][Full Text] [Related]
13. Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer.
Masoodi T; Siraj AK; Siraj S; Azam S; Qadri Z; Albalawy WN; Parvathareddy SK; Al-Sobhi SS; Al-Dayel F; Alkuraya FS; Al-Kuraya KS
Thyroid; 2020 Jan; 30(1):42-56. PubMed ID: 31668133
[No Abstract] [Full Text] [Related]
14. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis.
Walts AE; Pao A; Sacks W; Bose S
Hum Pathol; 2014 May; 45(5):935-41. PubMed ID: 24746198
[TBL] [Abstract][Full Text] [Related]
15. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
17. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes.
Vasko V; Hu S; Wu G; Xing JC; Larin A; Savchenko V; Trink B; Xing M
J Clin Endocrinol Metab; 2005 Sep; 90(9):5265-9. PubMed ID: 15998781
[TBL] [Abstract][Full Text] [Related]
18. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
19. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.
Kim J; Giuliano AE; Turner RR; Gaffney RE; Umetani N; Kitago M; Elashoff D; Hoon DS
Ann Surg; 2006 Nov; 244(5):799-804. PubMed ID: 17060774
[TBL] [Abstract][Full Text] [Related]
20. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
